Upstream Bio (UPB) Current Assets (2023 - 2026)
Upstream Bio (UPB) posted quarterly Current Assets of $316.3 million for Q1 2026, down 30.3% year-over-year from $453.8 million in Q1 2025, and down 10.1% quarter-over-quarter from $351.8 million in Q4 2025.
Upstream Bio (UPB) Current Assets (2023 - 2026) Analysis & Trends
Upstream Bio's Current Assets history runs 4 years deep, the most recent figure standing at $316.3 million for Q1 2026.
- In Q1 2026, Current Assets fell 30.3% year-over-year to $316.3 million; the TTM figure through Mar 2026 stood at $316.3 million (down 30.3% YoY), while the FY2025 annual figure was $351.8 million, down 26.58% from the prior year.
- Current Assets for Q1 2026 stood at $316.3 million, down from $351.8 million in the prior quarter.
- The five-year high for Current Assets was $479.2 million in Q4 2024, with the low at $117.0 million in Q4 2023.
- The 4-year median for Current Assets is $370.4 million (2025), against an average of $344.1 million.
- The sharpest annual moves came in 2024 and 2026: Current Assets soared 309.55% in 2024, then sank 30.3% in 2026.
- Upstream Bio's Current Assets stood at $117.0 million in 2023, then jumped by 309.55% to $479.2 million in 2024, then dropped by 26.58% to $351.8 million in 2025, then fell by 10.1% to $316.3 million in 2026.
- Business Quant data shows UPB's Current Assets at $316.3 million in Q1 2026, $351.8 million in Q4 2025, and $389.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 279.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 279.60 Mn |
| Mar 31, 2026 | 316.28 Mn |
| Dec 31, 2025 | 351.80 Mn |
| Sep 30, 2025 | 389.02 Mn |
| Jun 30, 2025 | 418.27 Mn |
| Mar 31, 2025 | 453.79 Mn |
| Dec 31, 2024 | 479.16 Mn |
| Sep 30, 2024 | 227.27 Mn |
| Dec 31, 2023 | 117.00 Mn |